Familial Hypercholesterolaemia (FHc) is a common inherited disorder, leading to raised serum cholesterol evident from the first year of life. One in 500 people are affected by the minor heterozygote form of this condition, of which an estimated 85% are unidentified. National English guidelines, produced by NICE, highlight the importance of cholesterol screening and FHc identification in prevention of coronary heart disease [1, 2]. However, evidence based approaches to support guideline implementation are under developed. The incorporation of computerised patient specific reminders is thought to have clinical utility in the identification of patients with genetic conditions but as yet not evaluated in primary care for FHc.